• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by RVL Pharmaceuticals plc (Amendment)

    8/11/22 3:53:01 PM ET
    $RVLP
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $RVLP alert in real time by email
    SC 13G/A 1 d396922dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G/A

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED

    PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    RVL Pharmaceuticals plc

    (Name of Issuer)

    Ordinary Shares, nominal value $0.01 per share

    (Title of Class of Securities)

    G6S41R101

    (CUSIP Number)

    August 8, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐

    Rule 13d-1(b)

     

      ☒

    Rule 13d-1(c)

     

      ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP NO. G6S41R101    13G    Page 2 of 13 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      ATHYRIUM OPPORTUNITIES IV ACQUISITION 2 LP

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      STATE OF DELAWARE, UNITED STATES OF AMERICA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0 Ordinary Shares

       6  

      SHARED VOTING POWER

     

      8,148,832 Ordinary Shares

       7  

      SOLE DISPOSITIVE POWER

     

      0 Ordinary Shares

       8  

      SHARED DISPOSITIVE POWER

     

      8,148,832 Ordinary Shares

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      8,148,832 Ordinary Shares

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      8.23% of the outstanding Ordinary Shares

    12  

      TYPE OF REPORTING PERSON

     

      PN    


    CUSIP NO. G6S41R101    13G    Page 3 of 13 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      ATHYRIUM OPPORTUNITIES ASSOCIATES IV LP

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      STATE OF DELAWARE, UNITED STATES OF AMERICA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0 Ordinary Shares

       6  

      SHARED VOTING POWER

     

      8,148,832 Ordinary Shares

       7  

      SOLE DISPOSITIVE POWER

     

      0 Ordinary Shares

       8  

      SHARED DISPOSITIVE POWER

     

      8,148,832 Ordinary Shares

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      8,148,832 Ordinary Shares

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      8.23% of the outstanding Ordinary Shares

    12  

      TYPE OF REPORTING PERSON

     

      PN    

     


    CUSIP NO. G6S41R101    13G    Page 4 of 13 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      ATHYRIUM OPPORTUNITIES ASSOCIATES IV GP LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      STATE OF DELAWARE, UNITED STATES OF AMERICA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0 Ordinary Shares

       6  

      SHARED VOTING POWER

     

      8,148,832 Ordinary Shares

       7  

      SOLE DISPOSITIVE POWER

     

      0 Ordinary Shares

       8  

      SHARED DISPOSITIVE POWER

     

      8,148,832 Ordinary Shares

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      8,148,832 Ordinary Shares

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      8.23% of the outstanding Ordinary Shares

    12  

      TYPE OF REPORTING PERSON

     

      OO    


    CUSIP NO. G6S41R101    13G    Page 5 of 13 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      ATHYRIUM OPPORTUNITIES IV CO-INVEST 2 LP

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      STATE OF DELAWARE. UNITED STATES OF AMERICA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0 Ordinary Shares

       6  

      SHARED VOTING POWER

     

      6,451,612 Ordinary Shares

       7  

      SOLE DISPOSITIVE POWER

     

      0 Ordinary Shares

       8  

      SHARED DISPOSITIVE POWER

     

      6,451,612 Ordinary Shares

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      6,451,612 Ordinary Shares

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      6.52% of the outstanding Ordinary Shares

    12  

      TYPE OF REPORTING PERSON

     

      PN    

     


    CUSIP NO. G6S41R101    13G    Page 6 of 13 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      ATHYRIUM OPPORTUNITIES ASSOCIATES IV CO-INVEST LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      STATE OF DELAWARE, UNITED STATES OF AMERICA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0 Ordinary Shares

       6  

      SHARED VOTING POWER

     

      6,451,612 Ordinary Shares

       7  

      SOLE DISPOSITIVE POWER

     

      0 Ordinary Shares

       8  

      SHARED DISPOSITIVE POWER

     

      6,451,612 Ordinary Shares

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      6,451,612 Ordinary Shares

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      6.52% of the outstanding Ordinary Shares

    12  

      TYPE OF REPORTING PERSON

     

      OO

     


    CUSIP NO. G6S41R101    13G    Page 7 of 13 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      ATHYRIUM FUNDS GP HOLDINGS LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      STATE OF DELAWARE, UNITED STATES OF AMERICA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0 Ordinary Shares

       6  

      SHARED VOTING POWER

     

      14,600,444 Ordinary Shares

       7  

      SOLE DISPOSITIVE POWER

     

      0 Ordinary Shares

       8  

      SHARED DISPOSITIVE POWER

     

      14,600,444 Ordinary Shares

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      14,600,444 Ordinary Shares

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      14.75% of the outstanding Ordinary Shares

    12  

      TYPE OF REPORTING PERSON

     

      OO

     


    CUSIP NO. G6S41R101    13G    Page 8 of 13 Pages

     

      1    

      NAMES OF REPORTING PERSONS

     

      Jeffrey A. Ferrell

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      UNITED STATES OF AMERICA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0 Ordinary Shares

       6  

      SHARED VOTING POWER

     

      14,600,444 Ordinary Shares

       7  

      SOLE DISPOSITIVE POWER

     

      0 Ordinary Shares

       8  

      SHARED DISPOSITIVE POWER

     

      14,600,444 Ordinary Shares

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      14,600,444 Ordinary Shares

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      14.75% of the outstanding Ordinary Shares

    12  

      TYPE OF REPORTING PERSON

     

      IN

     


    CUSIP NO. G6S41R101    13G    Page 9 of 13 Pages

     

    Item 1(a).

    Name of Issuer:

    RVL Pharmaceuticals plc (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    400 Crossing Boulevard

    Bridgewater, New Jersey 08807

     

    Item 2(a).

    Name of Person Filing:

    This statement (this “Statement”) is filed by the following persons (the “Reporting Persons”):

    Athyrium Opportunities IV Acquisition 2 LP (“Acquisition Fund”)

    Athyrium Opportunities Associates IV LP (“Associates IV LP”)

    Athyrium Opportunities Associates IV GP LLC (“Associates IV GP”)

    Athyrium Opportunities IV Co-Invest 2 LP (“Co-Invest 2 LP”)

    Athyrium Opportunities Associates IV Co-Invest LLC (“Co-Invest LLC”)

    Athyrium Funds GP Holdings LLC (“Funds GP Holdings”)

    Jeffrey A. Ferrell (“Mr. Ferrell”)

    The Reporting Persons’ beneficial ownership of the Issuer’s Ordinary Shares reported herein consist of ordinary shares, nominal value $0.01 per share, held directly by Acquisition Fund and Co-Invest 2 LP.

    Pursuant to Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the Reporting Persons have entered into an agreement with respect to the joint filing of this Statement, which agreement is set forth on the signature page to this Statement.

     

    Item 2(b).

    Address of Principal Business Office or, if none, Residence:

    The principal business office address for each of the Reporting Persons is:

    c/o Athyrium Capital Management, LP

    505 Fifth Avenue, Floor 18

    New York, New York 10017

     

    Item 2(c).

    Citizenship:

    Acquisition Fund, Co-Invest 2 LP and Associates IV LP are Delaware limited partnerships.

    Associates IV GP, Co-Invest LLC and Funds GP Holdings are Delaware limited liability companies.

    Mr. Ferrell is a United States citizen.

     

    Item 2(d).

    Title of Class of Securities:

    Ordinary Shares, nominal value $0.01 per share, of the Issuer (the “Ordinary Shares”)

     

    Item 2(e).

    CUSIP Number:

    G6S41R101


    CUSIP NO. G6S41R101    13G    Page 10 of 13 Pages

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable. Filed pursuant to Rule 13d-1(c).

     

    Item 4.

    Ownership.

     

      (a)

    Amount beneficially owned:

    The Reporting Persons beneficially own in the aggregate 14,600,444 Ordinary Shares. In addition, certain of the Reporting Persons beneficially own warrants (the “Warrants”) to purchase 2,000,000 Ordinary Shares. However, because the terms of the Warrants limit the exercise of the Warrants while the Reporting Persons’ beneficial ownership of the Issuer’s Ordinary Shares exceeds 9.9% of the outstanding Ordinary Shares, the Warrants held by the Reporting Persons do not represent a right to receive Ordinary Shares within 60 days of the date of this Statement and therefore none of the shares issuable upon exercise of the Warrants are included herein.

     

      (b)

    Percent of class:

    See the responses to Item 11 on the attached cover pages.

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote:

    See the responses to Item 5 on the attached cover pages.

     

      (ii)

    Shared power to vote or to direct the vote:

    See the responses to Item 6 on the attached cover pages.

     

      (iii)

    Sole power to dispose or to direct the disposition of:

    See the responses to Item 7 on the attached cover pages.

     

      (iv)

    Shared power to dispose or to direct the disposition of:

    See the responses to Item 8 on the attached cover pages.

    The filing of this Statement shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any securities of the Issuer that he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following  ☐.


    CUSIP NO. G6S41R101    13G    Page 11 of 13 Pages

     

    Item 6.

    Ownership of More Than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    CUSIP NO. G6S41R101    13G    Page 12 of 13 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this Statement is true, complete and correct.

    In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of this Statement on Schedule 13G with respect to the Ordinary Shares of the Issuer.

    Dated: August 11, 2022

     

    ATHYRIUM OPPORTUNITIES IV ACQUISITION 2 LP
    By:   ATHYRIUM OPPORTUNITIES ASSOCIATES IV LP, its General Partner
      By:   ATHYRIUM OPPORTUNITIES ASSOCIATES IV GP LLC, its General Partner
      By:  

    /s/ Andrew Hyman

      Name:   Andrew Hyman
      Title:   Senior Vice President, Secretary

     

    ATHYRIUM OPPORTUNITIES ASSOCIATES IV LP
    By:   ATHYRIUM OPPORTUNITIES ASSOCIATES IV GP LLC, its General Partner
    By:  

    /s/ Andrew Hyman

    Name:   Andrew Hyman
    Title:   Senior Vice President, Secretary
    ATHYRIUM OPPORTUNITIES ASSOCIATES IV GP LLC
    By:  

    /s/ Andrew Hyman

    Name:   Andrew Hyman
    Title:   Senior Vice President, Secretary


    CUSIP NO. G6S41R101    13G    Page 13 of 13 Pages

     

    ATHYRIUM OPPORTUNITIES IV CO-INVEST 2 LP
    By: ATHYRIUM OPPORTUNITIES ASSOCIATES IV CO-INVEST LLC, its General Partner
    By:  

    /s/ Andrew Hyman

    Name:   Andrew Hyman
    Title:   Senior Vice President, Secretary
    ATHYRIUM OPPORTUNITIES ASSOCIATES IV CO-INVEST LLC
    By:  

    /s/ Andrew Hyman

    Name:   Andrew Hyman
    Title:   Senior Vice President, Secretary
    ATHYRIUM FUNDS GP HOLDINGS LLC
    By:  

    /s/ Jeffrey A. Ferrell

    Name:   Jeffrey A. Ferrell
    Title:   Managing Member

     

    /s/ Jeffrey A. Ferrell

    JEFFREY A. FERRELL
    Get the next $RVLP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RVLP

    DatePrice TargetRatingAnalyst
    10/21/2022$2.50Hold
    Jefferies
    4/5/2022$4.00Overweight
    Barclays
    More analyst ratings

    $RVLP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • RVL Pharmaceuticals plc Announces Prepackaged Reorganization of Certain U.S. Subsidiaries

      Lender to Provide Incremental Liquidity to Support Long-Term Growth Senior Secured Lender to Exchange Outstanding Debt into Equity of the Reorganized Entities Business Operations at U.S. Subsidiaries to Continue as They Pursue Strategic Plan RVLP Ordinary Shares Expected to be Cancelled BRIDGEWATER, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc ("RVL" or "the Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or droopy eyelid, in adults, today announced that certain of its U.S. operating subsidiaries, RevitaLid Pharmaceutical C

      10/12/23 6:50:00 AM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care
    • RVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment Conference

      BRIDGEWATER, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company, today announced that Brian Markison, Chief Executive Officer, will participate in a fireside chat and host 1x1 investor meetings at the H.C. Wainwright 25th Annual Global Investment Conference in New York City as follows: Date:Tuesday, September 12, 2023  Time:11:30 am ET  Webcast:Click here To schedule a 1x1 investor meeting with the Company, please contact [email protected] at H.C. Wainwright. The live and archived webcast of the fireside chat will be accessible from the Company's website at www.rvlpharma.com, under the Investors & New

      8/23/23 4:05:00 PM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care
    • RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

      BRIDGEWATER, N.J., Aug. 16, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, today announced that it has entered into definitive agreements for the purchase and sale of 11,870,846 of its ordinary shares (or ordinary share equivalents in lieu thereof) at a purchase price of $0.4212 per ordinary share (or ordinary share equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. The Company also agreed

      8/16/23 8:00:00 AM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care

    $RVLP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Harsaul Foundation sold $580,147 worth of Ordinary Shares (14,122,659 units at $0.04) (SEC Form 4)

      4 - RVL Pharmaceuticals plc (0001739426) (Issuer)

      10/23/23 4:23:52 PM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care
    • Altchem Ltd sold $580,147 worth of Ordinary Shares (14,122,659 units at $0.04), decreasing direct ownership by 74% to 4,941,101 units (SEC Form 4)

      4 - RVL Pharmaceuticals plc (0001739426) (Issuer)

      10/23/23 1:06:00 PM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care
    • Harsaul Foundation sold $221,031 worth of Ordinary Shares (3,421,537 units at $0.06) (SEC Form 4)

      4 - RVL Pharmaceuticals plc (0001739426) (Issuer)

      10/20/23 3:59:45 PM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care

    $RVLP
    Financials

    Live finance-specific insights

    See more

    $RVLP
    SEC Filings

    See more

    $RVLP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $RVLP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • RVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results; Provides Update on Strategic Business Review

      -- UPNEEQ® remains a significant potential value driver given its rapid early acceptance by providers, large total addressable market and untapped consumer opportunity -- -- Executed financing amendment with Athyrium, which, subject to certain conditions, would provide meaningful flexibility as part of our ongoing strategy to invest in UPNEEQ and drive growth -- -- The Company is in discussions with strategic targets that could accelerate UPNEEQ sales, broaden the Company's portfolio and leverage the field force investment -- -- Second quarter 2023 UPNEEQ net product sales of $8.3 million and operating expenses of $14.4 million, down 2% and 32%, respectively, compared to the prior year pe

      8/14/23 6:50:51 AM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care
    • RVL Pharmaceuticals plc to Discuss Second Quarter 2023 Financial Results and Provide Commercial Update

      BRIDGEWATER, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that the Company will release its second quarter 2023 financial results and provide a commercial update on Monday, August 14, 2023, before U.S. financial markets open. Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Mike DePetris, Principal Accounting Officer, will host a conference call as follows: Date     Monday, August 14, 2023Time 8:30 a.m. ETRegister* (audio only) Click hereW

      8/2/23 8:30:00 AM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care
    • RVL Pharmaceuticals plc Reports First Quarter 2023 Financial Results; Provides Commercial Update

      -- First quarter 2023 UPNEEQ® net product sales grew 49%, or $2.9 million, over the prior year period to $8.8 million -- -- Enhanced operating leverage with a 32%, or $7.9 million, reduction in first quarter 2023 total operating expenditures from the prior year -- -- Majority of aesthetic orders in the first quarter, or 54%, represented reorder activity -- -- Approximately 4,800 cumulative unique medical aesthetics practices had placed orders for UPNEEQ through the end of the first quarter, a 12% increase from prior quarter end -- -- UPNEEQ Won "Best Eye Drop for Drooping Lids" NewBeauty in 13th Annual Beauty Awards, selected from among 10,000 entrants -- BRIDGEWATER, N.J., M

      5/11/23 6:50:55 AM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care
    • RVL Pharmaceuticals plc filed SEC Form 8-K: Other Events

      8-K - RVL Pharmaceuticals plc (0001739426) (Filer)

      2/13/24 4:05:38 PM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care
    • RVL Pharmaceuticals plc filed SEC Form 8-K: Other Events

      8-K - RVL Pharmaceuticals plc (0001739426) (Filer)

      1/17/24 4:05:41 PM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care
    • RVL Pharmaceuticals plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - RVL Pharmaceuticals plc (0001739426) (Filer)

      12/20/23 4:15:51 PM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care
    • Jefferies resumed coverage on RVL Pharmaceuticals with a new price target

      Jefferies resumed coverage of RVL Pharmaceuticals with a rating of Hold and set a new price target of $2.50

      10/21/22 7:38:37 AM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care
    • Barclays resumed coverage on RVL Pharmaceuticals with a new price target

      Barclays resumed coverage of RVL Pharmaceuticals with a rating of Overweight and set a new price target of $4.00

      4/5/22 7:57:14 AM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13D/A filed by RVL Pharmaceuticals plc (Amendment)

      SC 13D/A - RVL Pharmaceuticals plc (0001739426) (Subject)

      11/27/23 9:24:25 PM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13D/A filed by RVL Pharmaceuticals plc (Amendment)

      SC 13D/A - RVL Pharmaceuticals plc (0001739426) (Subject)

      11/1/23 4:27:14 PM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13D/A filed by RVL Pharmaceuticals plc (Amendment)

      SC 13D/A - RVL Pharmaceuticals plc (0001739426) (Subject)

      10/13/23 5:28:49 PM ET
      $RVLP
      Pharmaceuticals and Biotechnology
      Health Care